The private sector has little appetite for manufacturing small-volume, niche vaccines for pandemic viruses. That’s why any primary manufacturing facility for vaccines like COVID-19 need to be federally owned and operated.
Topic: vaccine manufacturing
The Short Report, May 13, 2020: Public trust in science rising; new COVID-19 advisory councils created; OneEleven ceases operations; and more
COVID-19 NEWS Canadians’ trust in doctors, scientists and the government has increased since the cornovirus pandemic began, finds public opinion polls from January and repeated on May 1 and May 2. Conducted by Proof Strategies CanTrust Index of Ottawa, the survey found that 76% of Canadians trusted doctors and 70% trusted scientists. The follow up…
The Short Report, May 6, 2020: AbCellera receives $175.6M for COVID-19 therapies; Canada contributes $850 million to global pandemic response; new “super angel” fund launches; and more
Vancouver-based AbCellera Biologics will receive up to $175.6 million from the federal Strategic Innovation Fund to fast-track antibody therapies against COVID-19. The funding will also go to build a first-of-its-kind antibody manufacturing facility over the next four years to help Canada respond to future pandemics. AbCellera has partnered with global biopharmaceutical company Eli Lilly to…
Applied PeR$pectives
Building with CCNB-INNOV… Relationships that go a Long Way! CCNB-INNOV, the applied research and development arm of CCNB has adapted its range of services to better meet the unique needs of the regional shipbuilding industry.
 |
Applied PeR$pectives is a new monthly blog dedicated to highlighting the innovative work being done in the college and institute community. |
|---|
Fast Policy Facts
 |
December 12, 2018: Requiem for a National Network Program
|
|---|
Research Money on Twitter
Loading tweets...